BBHC
HRTX icon

Brown Brothers Harriman & Co’s Heron Therapeutics HRTX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-25
Closed -$1K – 842
2018
Q2 		$1K Buy
+25
New +$796 ﹤0.01% 797

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Brown Brothers Harriman & Co's HRTX Position: Q3 2018 in Review

Brown Brothers Harriman & Co sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 25 shares — an estimated $1K sold.

Brown Brothers Harriman & Co first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

  • Brown Brothers Harriman & Co reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 25 Heron Therapeutics shares in Q3 2018, an estimated $1K.
  • Brown Brothers Harriman & Co first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Heron Therapeutics position peaked at $1K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2018, filed 14 Nov 2018.